Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01812668 · ClinicalTrials.gov registry record · NA
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01812668: Completed NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT01812668 is a NA study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01812668, a NA study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Primary Outcome
Change in PET standard uptake value SUV levels (each value measured in g/ml). (post-treatment - pre-treatment)/pre-treatment x 100 , therefore, measured in percentage change from baseline.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- PROCEDURE positron emission tomography
- DRUG cabozantinib-s-malate
- RADIATION fluorine F 18 d-FMAU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-03 |
| Est. Completion | 2019-06-18 |
| Phase | NA |
What the finished NCT01812668 record still lists
NCT01812668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01812668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01812668 about?
NCT01812668 is a clinical study titled "Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer". This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT01812668?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2013-03. Estimated completion is 2019-06-18.
What interventions are being tested in trial NCT01812668?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), positron emission tomography (PROCEDURE), cabozantinib-s-malate (DRUG), fluorine F 18 d-FMAU (RADIATION).
Who is sponsoring clinical trial NCT01812668?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01812668's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia